ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Phaxiam Therapeutics

Phaxiam Therapeutics (0QSS)

71.025
0.00
(0.00%)
Closed January 04 11:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
71.025
Bid
6.925
Ask
7.28
Volume
8
0.00 Day's Range 0.00
71.025 52 Week Range 71.025
Market Cap
Previous Close
71.025
Open
-
Last Trade
8
@
1.712
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
5
Shares Outstanding
6,075,000
Dividend Yield
-
PE Ratio
-0.44
Earnings Per Share (EPS)
-3.87
Revenue
1.33M
Net Profit
-23.49M

About Phaxiam Therapeutics

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Lyon, Rhone, Fra
Founded
-
Phaxiam Therapeutics is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QSS. The last closing price for Phaxiam Therapeutics was 71.03 €. Over the last year, Phaxiam Therapeutics shares have traded in a share price range of 71.025 € to 71.025 €.

Phaxiam Therapeutics currently has 6,075,000 shares outstanding. The market capitalization of Phaxiam Therapeutics is 431.48 € million. Phaxiam Therapeutics has a price to earnings ratio (PE ratio) of -0.44.

0QSS Latest News

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024 Article 223-16 du Règlement Général de...

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024 Article 223-16 of general regulation of French...

PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie

PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie Tenue d’un webinaire le 27 novembre 2024 « Evolving strategic...

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area Webinar being held today "Evolving strategic context for phages...

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » PHAXIAM a présenté son test IVD Phagogramme et l’actualisation...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility...

PHAXIAM Reports Third-Quarter 2024 Financial Information

PHAXIAM Reports Third-Quarter 2024 Financial Information Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase...

PHAXIAM publie l’information financière du troisième trimestre 2024

PHAXIAM publie l’information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie de 5,7 M€ au 30 septembre 2024Exécution de la stratégie clinique conforme au plan, avec...

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Monthly information related to total number of voting rights and shares...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Information mensuelle relative au nombre total de droits de vote et...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10071.02571.02571.025271.025DE
40071.02571.02571.025171.025DE
120071.02571.02571.025571.025DE
260071.02571.02571.025371.025DE
520071.02571.02571.025371.025DE
1560071.02571.02571.025149971.025DE
2600071.02571.02571.025195971.025DE

0QSS - Frequently Asked Questions (FAQ)

What is the current Phaxiam Therapeutics share price?
The current share price of Phaxiam Therapeutics is 71.025 €
How many Phaxiam Therapeutics shares are in issue?
Phaxiam Therapeutics has 6,075,000 shares in issue
What is the market cap of Phaxiam Therapeutics?
The market capitalisation of Phaxiam Therapeutics is EUR 431.48M
What is the 1 year trading range for Phaxiam Therapeutics share price?
Phaxiam Therapeutics has traded in the range of 71.025 € to 71.025 € during the past year
What is the PE ratio of Phaxiam Therapeutics?
The price to earnings ratio of Phaxiam Therapeutics is -0.44
What is the cash to sales ratio of Phaxiam Therapeutics?
The cash to sales ratio of Phaxiam Therapeutics is 7.79
What is the reporting currency for Phaxiam Therapeutics?
Phaxiam Therapeutics reports financial results in EUR
What is the latest annual turnover for Phaxiam Therapeutics?
The latest annual turnover of Phaxiam Therapeutics is EUR 1.33M
What is the latest annual profit for Phaxiam Therapeutics?
The latest annual profit of Phaxiam Therapeutics is EUR -23.49M
What is the registered address of Phaxiam Therapeutics?
The registered address for Phaxiam Therapeutics is 60 AVENUE ROCKEFELLER, LYON, RHONE, 69008
What is the Phaxiam Therapeutics website address?
The website address for Phaxiam Therapeutics is www.phaxiam.com
Which industry sector does Phaxiam Therapeutics operate in?
Phaxiam Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
SSKILLZ1 SSKILLZ1 3 minutes ago
Anyways Hope everyone enjoys the stats and has fun this contest, I'm off to enjoy the rest of my weekend.
Slojab Slojab 3 minutes ago
Being Current Info is merely paperwork.

Producing a product that produces revenue is a wee bit harder. Frank hasn't ever managed to do that in over a decade in the OTC.

What's amusing is when people try and persuade others that this time will be different.
SANP
KILLAZILLA KILLAZILLA 5 minutes ago
NOBODY IS SHORTING ANY POS OTC .0000 POS SCAMS WITH DISMAL VOLUME....

DO you EVEN KNOW HOW MUCH SOMEONE WOULD HAVE TO PUT UP FOR SUCH LITTLE GAINS??? you DON'T BECAUSE you're AN UNINFORMED PATHETIC PUMPER...

WDLF
dstock07734 dstock07734 5 minutes ago
Gary,

Here is a phase 2 trial run by Daiichi with Merck as collaborator. The trial was started in 2021 which was before the collaboration deal between Merck and Daiichi on three ADCs.

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced
NWBO
SSKILLZ1 SSKILLZ1 7 minutes ago
The Picks For Pick 4 Contest #21

Commentary: We have 37 Contestants this contest. Well without further ado everyone's pick are below.
[pre]
Alias SP #1 SP #2 SP #3 SP #4
1 10NISMAN BNED BYON
AES AMRN APLD
dragoon76 dragoon76 8 minutes ago
He's a closet basher.
COOP
StayHumble StayHumble 9 minutes ago
Mother Earth’s Stores Double $HCWC💹Revenue to $75Million+💹@healthiercmc
https://www.healthiercmc.com/news/20220210-mother-earths-storehouse
https://static1.squarespace.com/static/58a1d7b8893fc0b6d3e47931/t/63599cf2e6708456f8187f4c/1666817273168/HCMC_LDMicroOct2022.pdf
HCWC
KILLAZILLA KILLAZILLA 10 minutes ago
So, your M.O. is to post MISLEADING GARBAGE.....GOT IT!!! Thanks for sharing

"but I’ll post here if I want."
MNMD
shurtha2000 shurtha2000 10 minutes ago
Happy new Year NewMedMan

https://www.youtube.com/watch?v=-s8E9LY8jJ8
SSKILLZ1 SSKILLZ1 11 minutes ago
Every Stock with Starting Price and # of Shares (In Alphabetical Order)

Commentary: This chart will help everyone set up there imaginary portfolios if they so desire. It gives the starting prices of each stock and the # of shares. Hope this helps.
[pre]
Symbol # Of Sha
AES AMRN APLD
Papes Papes 12 minutes ago
That means the folks that can buy before everyone else should do so soon ;-) $CLHI 
CLHI
Jay_B Jay_B 12 minutes ago
Perfect! Quick... someone find Chad, punch him in the balls and tell him it's time to man up for fux sake!
SFLM
sortagreen sortagreen 13 minutes ago
This is kind of... I don't know. Bizarre?

https://bsky.app/profile/polgreen.bsky.social/post/3lex6r7ja2s2q
moondogaz moondogaz 13 minutes ago
" tears of a clown"...generation...X...
HMBL
StayHumble StayHumble 13 minutes ago
💹wow 💹a $5M $HCMC 💹💹BUYBACK 💹 💹 💹

-A buyback of up to $5M of $HCMC common stock.

-A spinoff of certain HCMC assets into a new publicly traded company

-A stock dividend to $HCMC shareholders of the st
HCMC
shajandr shajandr 14 minutes ago
https://investorshub.advfn.com/uimage/uploads/2024/12/30/ppuyqfknltLolFunnyGIF.gif
MRGE
Mermelstein Mermelstein 14 minutes ago
INBP - yes last years CY Q4 was a bit strange, but that makes for a very easy comp this time around…which I like.
Covid kind of distorted financials over the last few years as their customers ordered too much inventory from 2020 to 2021, and then had to chew through that inventory from 2022-2
StayHumble StayHumble 14 minutes ago
"$UBQU has No plans for a reverse split💹InnovativeOutcomes Merger"
https://x.com/CorporateUbqu/status/1765510100628726105?s=20
https://investorshub.advfn.com/uimage/uploads/2024/12/21/hiinwubqu.png
"trust me bro i'm an insider too"
https://cdn.vox-cdn.com/uploads
UBQU
MartinLutherKing MartinLutherKing 15 minutes ago
it’s so undervalued everyone thinks it’s a scam
RNAZ
dstock07734 dstock07734 15 minutes ago
Horse,

Has it occurred to you that all the delays in publishing the JAMA paper and getting the filing package ready must be related to the possibility that NWBO had to wait for Merck to be ready. The working hours adopted by Merck in finishing the building 63A strike me as quite unusu
BCG NWBO
shajandr shajandr 16 minutes ago
Growing, Thriving, Scaling.

https://investorshub.advfn.com/uimage/uploads/2014/3/15/rxjof1landfill.jpg
FUNN
StayHumble StayHumble 16 minutes ago
💹wow 80-$95 INCOMING!💹 UCLA💹Xerox|Mercedes|Santander|AbbeyRoadInst|Chatsworth|Ernst&Young|Omnisport|PinsentMasons
https://www.dbmmgroup.com/wp-content/uploads/2024/03/DBMM_Creds_Deck_2024_2.pdf
https://investorshub.advfn.com/uimage/uploads/2024/12/23/betnvDBMMi
DBMM
skitahoe skitahoe 18 minutes ago
I wish that LP would simply say that NWBO won't apply to other regulators until the EDEN is either approved for commercial production, or close enough in their opinion to be ready by the time inspectors are checking the entire production facility.

Bashers can continue to state that NW
NWBO
excel excel 18 minutes ago
What team is Pickens playing for?
Unreal.

Your Recent History

Delayed Upgrade Clock